STE 401

Drug Profile

STE 401

Alternative Names: STE-401

Latest Information Update: 10 Aug 2016

Price : $50

At a glance

  • Originator Stemergie Biotechnology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Electron transport complex I inhibitors; Electron transport complex III inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioma

Highest Development Phases

  • Preclinical Glioma

Most Recent Events

  • 10 Aug 2016 Preclinical trials in Glioma in Switzerland (unspecified route)
  • 10 Aug 2016 STE 401 is available for licensing as of 10 Aug 2016. http://www.stemergie.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top